Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-75098 Alone and in Combination With Other Agents in Advanced Solid Tumors
NCT07226349Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Countries
- 4
01
Overview
Phase 1, open-label trial of BG-75098 in solid tumor (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
BG-75098
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07226349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226349.